Role of soluble EGFR, Fas, and Fas ligand in pelvic pain severity and their association with endometriosis in infertile woman: a case-control study

Fadhil Ahsan, Nanda Yuli Rahmawati, Fidyah Nanda Alditia, Alfin Firasy Mufid, Ashon Sa'adi, Sri Ratna Dwiningsih, M Y Ardianta Widyanugraha, Arif Tunjungseto, Budi Santoso
Growth factors (Chur, Switzerland) · 2026 · pp. 1–13 · doi:10.1080/08977194.2026.2656185 · PMID:41951405
other OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study found higher peritoneal sFasL levels in infertile women with pelvic pain and endometriosis, correlating with pain severity and differentiating endometriosis from controls.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text ⓘ

This case-control study of 87 infertile women undergoing diagnostic laparoscopy measured serum and peritoneal concentrations of soluble EGFR, sFas, and sFas ligand (sFasL) by ELISA and assessed pelvic pain intensity using the Visual Analog Scale (VAS). Peritoneal sFasL was significantly higher in women with pelvic pain and was associated with higher VAS scores, and sFasL was also linked with dysmenorrhea and dyspareunia. In endometriosis patients with pelvic pain, both serum and peritoneal sFasL were significantly elevated versus controls, and ROC analysis showed serum sFasL could distinguish endometriosis from controls (AUC 0.797). The paper explicitly notes that further research is needed to investigate sFasL’s regulatory role in endometriosis-related pain. This paper is centrally about endometriosis — it evaluates sFasL as a potential biomarker and examines its association with pelvic pain severity in infertile women with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis, a chronic inflammatory condition linked to pelvic pain and infertility, is characterized by immune dysfunction involving dysregulated apoptosis and cell proliferation. This case-control study included 87 infertile women undergoing diagnostic laparoscopy and assessed serum and peritoneal levels of sEGFR, sFas, and sFasL using ELISA. Pain intensity was evaluated via the Visual Analog Scale (VAS). Peritoneal sFasL concentrations were significantly higher in infertile women with pelvic pain (p = 0.012) and correlated with VAS scores (r = 0.261, p = 0.014). Serum and peritoneal sFasL levels were significantly elevated in endometriosis patients with pelvic pain compared to controls (p = 0.003, p = 0.002, respectively). Peritoneal sFasL levels were also associated with dysmenorrhea and dyspareunia. ROC analysis demonstrated that serum sFasL differentiated endometriosis from controls (AUC = 0.797, p < 0.001). These findings suggest that sFasL may serve as a potential noninvasive biomarker for endometriosis. Further research should investigate its regulatory role in endometriosis-related pain.
Full text 1,211 characters · extracted from oa-doi-fallback · click to expand
Abstract Endometriosis, a chronic inflammatory condition linked to pelvic pain and infertility, is characterized by immune dysfunction involving dysregulated apoptosis and cell proliferation. This case-control study included 87 infertile women undergoing diagnostic laparoscopy and assessed serum and peritoneal levels of sEGFR, sFas, and sFasL using ELISA. Pain intensity was evaluated via the Visual Analog Scale (VAS). Peritoneal sFasL concentrations were significantly higher in infertile women with pelvic pain (p = 0.012) and correlated with VAS scores (r = 0.261, p = 0.014). Serum and peritoneal sFasL levels were significantly elevated in endometriosis patients with pelvic pain compared to controls (p = 0.003, p = 0.002, respectively). Peritoneal sFasL levels were also associated with dysmenorrhea and dyspareunia. ROC analysis demonstrated that serum sFasL differentiated endometriosis from controls (AUC = 0.797, p < 0.001). These findings suggest that sFasL may serve as a potential noninvasive biomarker for endometriosis. Further research should investigate its regulatory role in endometriosis-related pain. Disclosure statement No potential conflict of interest was reported by the author(s).

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Outcome instruments

VAS-pain

Condition tags

endometriosisdysmenorrheadyspareuniainfertility

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
pubmed
last seen: 2026-06-11T06:15:06.289189+00:00
unpaywall
last seen: 2026-05-11T08:34:28.763810+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine